Triple Negative Breast Cancer

被引：36
|
作者：
Cetin, Idil [1 ]
Topcul, Mehmet [2 ]
机构：
[1] Istanbul Univ, Fac Sci, Dept Radiobiol, Istanbul, Turkey
[2] Istanbul Univ, Fac Sci, Dept Biol, Istanbul, Turkey
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 06期
关键词：
Triple negative breast cancer; poor prognosis; targeted therapy; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; MOLECULAR SUBTYPES; RISK-FACTORS; STEM-CELLS; PROGNOSTIC VALUE; BASAL; CHEMOTHERAPY; CARCINOMA; SURVIVAL;
D O I：
10.7314/APJCP.2014.15.6.2427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.
引用
收藏
页码：2427 / 2431
页数：5
相关论文
共 50 条
  • [21] Pathology of triple negative breast cancer
    Borri, Filippo
    Granaglia, Annarita
    SEMINARS IN CANCER BIOLOGY, 2021, 72 : 136 - 145
  • [22] Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer
    Hu, Ling
    Gu, Yunxia
    Xu, Wen
    Wang, Chao
    BMC CANCER, 2024, 24 (01)
  • [23] The advance of adjuvant treatment for triple-negative breast cancer
    Ge, Jingyu
    Zuo, Wenjia
    Chen, Yiyu
    Shao, Zhiming
    Yu, Keda
    CANCER BIOLOGY & MEDICINE, 2022, 19 (02) : 187 - 201
  • [24] Triple-Negative Breast Cancer Epidemiology and Management Options
    Dawood, Shaheenah
    DRUGS, 2010, 70 (17) : 2247 - 2258
  • [25] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2010, 15 : 49 - 56
  • [26] Progress in systemic therapy for triple-negative breast cancer
    Mo, Hongnan
    Xu, Binghe
    FRONTIERS OF MEDICINE, 2021, 15 (01) : 1 - 10
  • [27] Expression of Topoisomerase II-α in Triple Negative Breast Cancer
    Mrklic, Ivana
    Pogorelic, Zenon
    Capkun, Vesna
    Tomic, Snjezana
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (03) : 182 - 187
  • [28] Triple-Negative Breast Cancer: An Unmet Medical Need
    Hudis, Clifford A.
    Gianni, Luca
    ONCOLOGIST, 2011, 16 : 1 - 11
  • [29] Current usage of pembrolizumab in triple negative breast cancer (TNBC)
    O'Rourke, Harriet
    Hart, Christopher
    De Boer, Richard H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 253 - 261
  • [30] Significance of Histomorphology of Early Triple-Negative Breast Cancer
    Rubovszky, Gabor
    Horvath, Zsolt
    Toth, Erika
    Lang, Istvan
    Kasler, Miklos
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (04) : 823 - 831
12345